Lucida Medical key facts
as of Oct 2026- Developer of an artificial intelligence-based healthcare technology designed to assist clinicians in detecting and diagnosing cancer.
- Lucida Medical is valued at approximately $44.7M as of Oct 2026 (last reported valuation).
- It has raised $23.6M; the latest was Later Stage VC ($11.6M) in Mar 2026.
- Notable investors include Innovate UK, Creative Destruction Lab, The FSE Group, Cambridge Enterprise Ventures, XTX Ventures — 18 tracked in total.
- Status: Privately Held (backing).
Lucida Medical's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch Lucida Medical: the Monday email on marks, rounds and moves
Lucida Medical funding rounds
No funding rounds for Lucida Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Lucida Medical
18+Lucida Medical valuation
Lucida Medical's last reported valuation was $44.7 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
Lucida Medical investors
18 investors are on record for Lucida Medical, including Innovate UK, Creative Destruction Lab, The FSE Group and Cambridge Enterprise Ventures.
About Lucida Medical
Developer of an artificial intelligence-based healthcare technology designed to assist clinicians in detecting and diagnosing cancer. The company's technology develops imaging and multi-omics biomarkers and reporting tools using artificial intelligence and MRI to support cancer screening and diagnosis, enabling clinicians and physicians to make cancer detection accurate, accessible, cost-effective, and quick.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2019
- Employees
- 24
- Website
- lucidamedical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.